EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

The real‐world relationship between naltrexone/bupropion treatment and weight loss in Canada: A retrospective chart review

Sean Wharton, Elham Kamran, Lehana Thabane, Peter Yin, Rebecca Christensen

Clinical Obesity · 2025

DOI: 10.1111/cob.12724 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical Obesity, 2025. Verfasst von Sean Wharton und 4 weiteren Autor:innen. Beteiligte Einrichtung: Wharton Medical Clinic, Burlington, Ontario, Canada. Hauptthemen laut MEDLINE: Naltrexone, Weight Loss, Bupropion, Obesity. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bausch Health Canada.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study examined the change in weight at 6 months of naltrexone/bupropion (NB), a combination pharmacological therapy for weight management, in real‐world practice in Canada. The study was conducted through an observational, retrospective, single‐arm chart review of adult patients who attended the Wharton Medical Clinic in Ontario, Canada, between 2018 and 2021. The patients had a body mass index ≥30 or ≥27 kg/m 2 with at least one weight‐related comorbidity. They were prescribed NB, titrated from 1 (8 mg/90 mg) to 4 tablets daily, along with lifestyle modification. Approximately 52% of 468 participants completed 6 months of treatment and 48.7% titrated to the maximum dose of 4 tablets daily. Participants were mainly female, with mean age of 49.5 years and BMI 38.4 kg/m 2 . After 6 months, participants lost a mean of 4.23 kg (95% confidence interval [CI] −4.99, −3.47) or 4.05% (CI −4.77, −3.34) of body weight, with 42.5% losing at least 5% of their body weight and 15.5% losing at least 10%. The most frequent adverse events were nausea (5.7%), constipation (5.7%), and headache (2.5%). Participants also experienced decreased appetite (14.7%), decreased cravings (13.9%), decreased hunger (9.4%) and felt full sooner (2.5%), which are changes likely to result in sustained healthy food choices and improved quality of life. The 6‐month NB treatment adjunct to lifestyle modification in a real‐world population resulted in clinically significant weight loss.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NaltrexoneWeight LossBupropionObesityAnti-Obesity AgentsHumansRetrospective StudiesFemaleMiddle AgedMaleAdultOntarioBody Mass IndexTreatment OutcomeAgedDrug Therapy, Combination

Stichwörter der Autor:innen

bupropionnaltrexoneobesityreal‐world evidenceweight loss management

Substanzen

NaltrexoneBupropionAnti-Obesity Agents

Autor:innen und Institutionen

  • Wharton Medical Clinic, Burlington, Ontario, Canada.
  • Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.
  • Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.
  • Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
  • Research Institute of St Joe's Hamilton, St Joseph's Healthcare Hamilton, Hamilton, Ontario, Canada.
  • Bausch Health, Quebec, Canada.

Förderung

  • Bausch Health Canada

Zitieren

APA

Wharton, S., Kamran, E., Thabane, L., Yin, P., & Christensen, R. (2025). The real‐world relationship between naltrexone/bupropion treatment and weight loss in Canada: A retrospective chart review. Clinical Obesity. https://doi.org/10.1111/cob.12724

Vancouver

Wharton S, Kamran E, Thabane L, Yin P, Christensen R. The real‐world relationship between naltrexone/bupropion treatment and weight loss in Canada: A retrospective chart review. Clinical Obesity. 2025. doi:10.1111/cob.12724

BibTeX
@article{Wharton2025,
  author = {Wharton, Sean and Kamran, Elham and Thabane, Lehana and Yin, Peter and Christensen, Rebecca},
  title = {The real‐world relationship between naltrexone/bupropion treatment and weight loss in Canada: A retrospective chart review},
  journal = {Clinical Obesity},
  year = {2025},
  doi = {10.1111/cob.12724}
}
Kostenlos starten →